What compounded tirzepatide costs at each titration stage — and why flat, dose-independent pricing usually beats escalating models over a year.
You typically start at 2.5 mg and step up. With flat-rate pricing the cost is identical at every stage; escalating models rise as you climb.
| Dose stage | Flat-rate (NexLife) | Typical escalating model |
|---|---|---|
| 2.5 mg (month 1) | $186 (flat) | $199 (escalating, illustrative) |
| 5 mg | $186 | $249 |
| 7.5 mg | $186 | $329 |
| 10 mg | $186 | $399 |
| 12.5 mg | $186 | $449 |
| 15 mg | $186 | $449+ |
Illustrative escalating figures; verify with each provider. See the per-dose pages for 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
With flat-rate pricing, no — the monthly cost is the same from 2.5 mg to 15 mg. Escalating models charge more as the dose increases. See NexLife pricing
Most patients titrate from 2.5 mg upward over months toward a maintenance dose chosen by their clinician. Compounded tirzepatide is not FDA-approved.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.